Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18576562 | 0.84 | KMT2A (0.57) | KMT2ABACE1HTTCYP1A2HIF1A | |
| SCHEMBL903366 | 0.81 | ALDH1A1 (0.40) | KMT2AHTTCYP1A2HIF1AALDH1A1 | |
| SCHEMBL30320818 | 0.80 | KMT2A (0.53) | KMT2ABACE1HTTCYP1A2HIF1A | |
| SCHEMBL8356501 | 0.80 | KMT2A (0.53) | KMT2ABACE1HTTCYP1A2HIF1A | |
| SCHEMBL1973599 | 0.79 | HTT (0.55) | KMT2AHTTCYP1A2TSHRGAA | |
| SCHEMBL5550440 | 0.79 | HTT (0.55) | KMT2AHTTCYP1A2TSHRGAA | |
| SCHEMBL9326232 | 0.77 | KMT2A (0.61) | KMT2ABACE1HTTGAANPSR1 | |
| SCHEMBL22860806 | 0.77 | KMT2A (0.61) | KMT2ABACE1HTTGAANPSR1 | |
| SCHEMBL15123413 | 0.73 | KMT2A (0.46) | KMT2ABACE1HTT | |
| SCHEMBL15123414 | 0.73 | KMT2A (0.46) | KMT2ABACE1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-20180194802-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2018-07-12 | — | — | US | disclosed |
| US-9850277-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170057994-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-03-02 | — | — | US | disclosed |
| US-20170015703-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-01-19 | — | — | US | disclosed |
| US-9474779-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160130298-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-05-12 | — | — | US | disclosed |
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KMT2A 87/4885BACE1 1850/4885HTT 303/4885 |
| US-20170015703-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KMT2A 185/4885BACE1 1117/4885HTT 204/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | KMT2A 3449/4885BACE1 225/4885HTT 3193/4885 |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KMT2A 185/4885BACE1 1117/4885HTT 204/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | KMT2A 87/4885BACE1 1850/4885HTT 303/4885 |
| US-20160130298-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KMT2A 185/4885BACE1 1117/4885HTT 204/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | KMT2A 3449/4885BACE1 225/4885HTT 3193/4885 |
| US-20180194802-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KMT2A 185/4885BACE1 1117/4885HTT 204/4885 |
| US-20170057994-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KMT2A 87/4885BACE1 1850/4885HTT 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.